Roche Reports the US FDA’s Approval of Xolair for Treating Food Allergies
Shots:
- The US FDA grants approval to Roche’s Xolair (omalizumab) for reducing allergic reactions like anaphylaxis caused by accidental exposure to one or more foods in IgE-mediated food allergic adult and pediatric patients (1yr. & above)
- The approval was supported by results of the P-III (OUtMATCH) trial assessing Xolair vs PBO for reducing allergy in patients (1yr. to 55yrs.) due to peanuts and at least two other food allergens
- The results demonstrated that treatment with Xolair after 16-20wks. showed tolerance of 600mg peanut protein (68% vs 5%), 1,000mg protein from milk (66% vs 11%), egg (67% vs 0%) or cashew (42% vs 3%) without moderate to severe allergic symptoms was seen in high no. of patients
Ref: Roche | Image: Roche
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
